Ipsen, Gen­fit un­veil ad­di­tion­al PhI­II da­ta for rare liv­er dis­ease drug, fur­ther boost­ing reg­u­la­to­ry am­bi­tion

Ipsen and Gen­fit re­vealed on Mon­day that their pri­ma­ry bil­iary cholan­gi­tis (PBC) drug can­di­date has met ad­di­tion­al end­points in a reg­is­tra­tional tri­al, adding fu­el to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER